These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34677192)

  • 1. Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Akkaif MA; Sha'aban A; Daud NAA; Yunusa I; Ng ML; Sk Abdul Kader MA; Noor DAM; Ibrahim B
    J Cardiovasc Dev Dis; 2021 Sep; 8(10):. PubMed ID: 34677192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Zhao X; Zhang J; Guo J; Wang J; Pan Y; Zhao X; Sang W; Yang K; Xu F; Xu F; Chen Y
    Front Pharmacol; 2021; 12():743259. PubMed ID: 34721032
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
    Yoon HY; Lee N; Seong JM; Gwak HS
    Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Barbarawi M; Zayed Y; Hicks M; Ahmed S; Bachuwa G; Hassan M; Bhatt DL
    J Thromb Thrombolysis; 2018 Oct; 46(3):299-303. PubMed ID: 29934940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Al-Abdouh A; Barbarawi M; Abusnina W; Amr M; Zhao D; Savji N; Hasan RK; Michos ED
    Cardiovasc Revasc Med; 2020 Dec; 21(12):1613-1618. PubMed ID: 32513604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis.
    Jiang Z; Liu L; Bundhun PK
    Diabetes Ther; 2023 Feb; 14(2):387-399. PubMed ID: 36542307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.
    Brown O; Rossington J; Buchanan GL; Patti G; Hoye A
    Curr Vasc Pharmacol; 2019; 17(2):191-203. PubMed ID: 29359672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis.
    Fujisaki T; Kuno T; Ando T; Briasoulis A; Takagi H; Bangalore S
    Am Heart J; 2021 Jul; 237():34-44. PubMed ID: 33737060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of dyspnea in patients treated with third-generation P2Y
    Zhang N; Xu W; Li O; Zhang B
    BMC Cardiovasc Disord; 2020 Mar; 20(1):140. PubMed ID: 32183711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta-analysis.
    Chen W; Zhang C; Zhao J; Xu X; Dang H; Xiao Q; Li Y; Hou H
    Clin Cardiol; 2021 Apr; 44(4):488-494. PubMed ID: 33704801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
    Wu B; Lin H; Tobe RG; Zhang L; He B
    J Comp Eff Res; 2018 Mar; 7(3):281-291. PubMed ID: 29094604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
    Hong J; Turgeon RD; Pearson GJ
    Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
    Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
    J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of High Potent P2Y
    Schreuder MM; Badal R; Boersma E; Kavousi M; Roos-Hesselink J; Versmissen J; Visser LE; Roeters van Lennep JE
    J Am Heart Assoc; 2020 Feb; 9(4):e014457. PubMed ID: 32063118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.